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Background and Purpose-Data on long-term survival and recurrence after stroke are 
lacking. We investigated time trends in ischemic stroke case-fatality and recurrence rates over 
20-years stratified by aetiological subtype according to the Trial of Org 10172 in Acute 
Stroke Treatment (TOAST) classification within a population-based stroke register in 
Germany. 
Methods-Data was collected within the Erlangen Stroke Project, a prospective, population-
based stroke register covering a source population of 105,164 inhabitants (2010). Case fatality 
and recurrence rates for 3months, 1year and 5years were estimated with Kaplan-Meier 
estimates. Sex-specific time trends for case-fatality and recurrence rates were estimated with 
Cox regression. We adjusted for age, sex and year of event and stratified for aetiological 
subtypes. A sensitivity analysis with competing risk analysis for time trends in recurrence 
were performed. 
Results-Between 1996 and 2015, 3,346 patients with first ischemic stroke were included; age-
standardized incidence per 100,000 was 75.8 in women and 131.6 in men (2015). Overall, 5-
year survival probabilities were 50.4% (95%-CI: 47.9-53.1) in women and 59.2% (95%-CI: 
56.4-62.0) in men; 5-year survival was highest in patients with first stroke due to small-artery 
occlusion (women: 71.8% (95%-CI: 67.1-76.9); men: 75.9% (95%-CI: 71.3-80.9)) and lowest 
in cardioembolic stroke (women: 35.7% (95%-CI: 31.0-41.1); men: 47.8% (95%-CI: 42.2-
54.3)). 5-year recurrence rates were 20.1% (95%-CI: 17.5-22.6) in women and 20.1% (95%-
CI 17.5-22.7) in men ; 5-year recurrence rate was lowest in women in stroke due to small 
artery occlusion 16.0% (95%-CI: 11.7-20.1) and in men in large-artery atherosclerosis 16.6% 
(95%-CI: (8.7-23.9); highest risk of recurrence was observed in undefined strokes (women: 
22.3% (95%-CI: 17.8-26.6); men: 21.4% (95%-CI: 16.7-25.9)). Cox regression revealed 
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improvements in case-fatality rates over time with differences in stroke aetiologies. No time 
trends in recurrence rates were observed. 
Conclusion-Long-term survival and recurrence varied substantially by first stroke aetiology. 
Survival probabilities improved over the last two decades, no major trends in stroke 
recurrence rates were observed. 
 
Non-standard Abbreviations and Acronyms 
CE    cardioembolism  
CI    Confidence Interval 
CFR    case-fatality rates 
HR    Hazard Ratio 
LAA    large-artery atherosclerosis 
OC    stroke of other determined cause  
SAO    small-artery occlusion  
TOAST     Trial of Org 10172 in Acute Stroke Treatment  






Based on routine mortality statistics ischemic stroke mortality decreased between 1998 and 
2015 about 50% in Germany1. It is unclear, to what extent this decline is attributable to 
changes in stroke incidence or to changes in case fatality and recurrence rates. Previous 
analysis from the Erlanger Stroke Project showed that ischemic stroke incidence in Germany 
decreased between 1995 to 2010 in men but not in women with substantial differences in 
aetiological subtypes of ischemic stroke according to the Trial of Org 10172 in Acute Stroke 
Treatment (TOAST) classification2. However, the burden of stroke in the population is not 
only influenced by incidence but also by case-fatality rates (CFR) as decreasing CFR 
accompanied by constant incidence rates leads to increasing prevalence3. Another important 
factor that drives the burden of stroke in the population are recurrence rates, because a second 
stroke is associated with a longer in-hospital stay, higher mortality and a higher degree of 
disability4, 5. 
Epidemiological data on the long-term time trends in CFR and recurrence rates in ischemic 
stroke patients are scarce. Recent publications from the population-based South London 
Stroke Register showed improved survival rates in all pathological subtypes of stroke6, 7. A 
systematic review showed that the 5-year stroke recurrence rates decreased over time across 
the 13 hospital- or community-based stroke registers included8. However, in the population of 
Perth in Australia no significant time trends in 5-year stroke recurrence rates were found9. 
CFR and recurrence rates differ substantially between aetiological subtypes of ischemic stroke 
based on TOAST criteria10-12. To the best of our knowledge, long-term data on patterns of 
CFR and recurrence rate from a population-based register stratified by ischemic stroke 




Therefore, by updating a prior analysis from the Erlangen Stroke Project from 1994-1996, we 
investigated long-term time trends in CFR and stroke recurrence rates by ischemic stroke 




The data that support the findings of this study are available from the corresponding author 
upon reasonable request. 
Erlanger Stroke Register 
The Erlanger Stroke Project is an ongoing prospective population-based stroke register in 
Germany, covering a source population of 105,164 inhabitants (2010). Within this source 
population incidence and outcome of stroke is continuously monitored since 1994. The 
methodology of the study has been described in detail elsewhere13. All hospitalized and non-
hospitalized stroke patients with registered residence in Erlangen were identified by regular 
checks of hospital admission, discharge records, nursing homes and general practices using 
standardized criteria to ensure completeness of case ascertainment13. Every patient is 
followed-up 3 months, 12 months and annually until death. Patients are contacted for follow-
up by study nurses and research assistants. In case the patient could not be contacted for 
follow-up, the Population Register of the City of Erlangen is checked for a possible change of 
address or death. If the patient died during the follow-up period, the death certificates is 
reviewed, and the cause of death is ascertained from all available medical records. 
Stroke was determined according to the WHO criteria14. Classification of pathological 
subtypes of stroke was determined based on brain CT or MRI scan, with 95% imaging rate13. 
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For the present analysis, patients with first-ever ischemic stroke from 1996 to 2015 were 
included.  
Aetiological subtype of ischemic stroke was defined according to Trial of Org 10172 in Acute 
Stroke Treatment (TOAST) classification15. We used the five major categories of TOAST: 
large-artery atherosclerosis (LAA) including large-artery thrombosis and artery-to-artery 
embolism, cardioembolism (CE), small-artery occlusion (SAO), stroke of other determined 
cause (OC) and stroke of undetermined cause (UND) comprising stroke of undefined and 
concurrent aetiology. Interrater reliability of the classification of TOAST for the present 
analysis was good (kappa=0.65 [95%-CI 0.35-0.96] between 1995 and 1998 and 0.63 [95%-CI 
0.43-0.83] between 1999 and 2010) as previously published2, 11. Recurrent stroke was defined 
as new neurological deficit at least 24 hours after the incident stroke according to the WHO 
definition excluding oedema, mass effect, brain shift syndrome or hemorrhagic transformation 
and procedure-related strokes16.  
 
Statistical Analysis 
Incidence rates were age-standardized according to the European standard population17. 
Recurrent stroke was defined as first recurrent stroke after the index event (ischemic stroke) 
regardless of the pathological subtype (ischemic, hemorrhagic stroke or other) of recurrent 
stroke. Crude 3 months, 1 year and 5 years CFR and recurrence rates at were estimated with 
Kaplan-Meier and stratified by sex and according to TOAST classification. Age-adjusted 
CFR and recurrence rates were estimated using Cox regression. Sex-specific time trends for 
CFR and recurrence rates were estimated Cox proportional hazard regression models. The 
Cox regression models were adjusted for age, sex and year of event and stratified by 
aetiological subtypes according to the TOAST classification. Due to the small sample size, 
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stroke of other determined cause was excluded in survival analysis. Competing risk analysis 
were performed as sensitivity analysis for time trends in recurrence rates18 with death from 
any cause being used as a competing event and recurrent stroke as an event of interest. 
Competing risk calculates the probability of getting a recurrent stroke under the condition that 
no recurrent event occurred before or that the person might have died. We used Aalen 
Johansen estimator to estimate the cumulative incidence as a function of recurrent stroke19. 
The subdistribution hazard regression from Fine and Gray was used to investigate time trends 
in the cumulative risk of recurrent stroke under competing risks adjusted for age, sex and 
stratified for aetiological subtype according to TOAST classification20.  
 
Ethics 
Written informed consent to participate was given by patients or their legal representatives. 
The study was approved by the Ethics Committee of the Medical Faculty of FAU Erlangen-
Nürnberg (Reference number: 249_15 Bc). 
 
Results 
Overall, 3,346 ischemic stroke patients were registered in the Erlanger Stroke Project between 
January 1996 to December 2015. Mean age was 74±13 years, 53.2% were women. 
Distribution of subtypes was as follows: LAA 8.4 %; CE 23.0%; SAO 28.0 %; OC 2.1%; and 
UND 38.5%. Mean age in years was 71±12 in LAA, 77±11 in CE, 71±12 in SAO, 58±17 in 
OC and 75±13 in UND; 41.5% of LAA, 56.7% of CE, 50.1% of SAO, 55.5% of SAO, 55.9% 
of OC and 55.5% of UND were women. The average annual age-standardized incidence rate 
of total ischemic stroke from 1996-2015 was 109.7 per 100,000 overall, 75.8 in women and 
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131.6 in men; average annual age-standardized incidence rate per stroke subtypes per 100,000 
was as follows: 11.2 in LAA; 22.7 in CE; 32.2 in SAO; 4.4 in OC; and 39.5 in UND. 
 
Case-fatality rates 
Overall, 3 month, 1-year and 5-year survival probabilities by sex and TOAST subtype are 
shown in Table 1 and Figure 1; 5-year survival probability was highest in patients with stroke 
due to SAO (73.8%, 95%-CI: 70.4-77.3) and lowest in CE stroke (40.9%, 95%-CI: 37.2–
45.0): Table 2 shows time trends determined by Hazard Ratios (HR) for the year of event of 
the adjusted Cox proportional hazard regression for death for the entire observation period as 
well as censored after 3 months, 1 year and 5 years. The same linear trends were observed in 
Kaplan-Meier survival estimates stratified for the year of event in 5-year groups with 1996-
2000 having the lowest and 2011-2015 having the highest survival rates (for details, please 
see https://www.ahajournals.org/journal/str, Figure I). Overall, Cox regression showed a trend 
for declining stroke mortality during the entire time period (HR for year of event 0.98, 95%-
CI: 0.97–0.99, p-value: <0.001). Stratified Cox regression revealed a significant decrease in 
stroke mortality over time in men as well as in women. Further significant decreases over 
time in stroke mortality were observed in CE in total as well as for men. In SAO we observed 
statistically significant declining stroke mortality rates in all for all and in women. In UND 
stroke mortality decreased significantly over time in total and in men.  
 
Stroke Recurrence 
Pathological subtypes of second strokes were as follows: 84.5% ischemic stroke; 5.7% 
intracerebral haemorrhage; 0.2% subarachnoid haemorrhage; and 9.6% stroke pathology not 
specified or missing. Overall, 3 month, 1-year and 5-year recurrence rates by sex and TOAST 
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subtype were shown in Table 3 and Figure 2. Undefined strokes had the highest (21.9%, 
CI:18.7-25.0) and SAO in women (16.0%, 95%-CI:11.7-20.1) and LAA in men (16.6%, 95%-
CI:8.7-23.9) the lowest rate of stroke recurrence after 5 years. There were no significant 
trends for decline in stroke recurrence estimated with Cox Regression (Table 4). In the 
sensitivity analysis taking death as competing risk into account the UND had the highest risk 
of recurrent stroke followed by SAO (for details please see 
https://www.ahajournals.org/journal/str , Table I). After considering death as competing risks, 
there were significant trends for a decline in stroke recurrence in all the patients. Stratified 
competing risk analysis showed significant decreases in risk of recurrent stroke in women and 
in women with UND (for details please see https://www.ahajournals.org/journal/str Table II). 
There was no linear trend in recurrence rates stratified for 5-year groups of year of event (for 
details please see https://www.ahajournals.org/journal/str Figure II).   
 
Discussion 
In our population-based sample, nearly every second patient died 5 years after the first event. 
There were substantial variations in survival rates across aetiological subtypes observed with 
highest rates for CE and lowest for SAO, respectively. CFR decreased over the 20 years of 
observation, showing similar trends across stroke aetiological subtypes except for LAA. 
About every fifth patient suffered from a recurrent stroke within 5 years after the first event 
with the highest recurrence rates observed in CE and UND. Cox Regression revealed no 
significant decrease in long-term recurrence rates over time. Competing risks analysis showed 




Our 3-month CFR of 13% are lower than the mean weighted CFR of 21.8% reported from the 
European Registers of Stroke (EROS) collaboration of six population-based stroke registers in 
Europe in 2004-2006, but similar to the lowest rate across the participating registers observed 
in Dijon21. On the other hand, the 1-year (63.7%) and 5-year survival rates (42.8%.) for 
ischemic and haemorrhagic stroke in the South London Stroke Register were lower compared 
to our study22. This might be caused by the fact that haemorrhagic strokes were included in 
the South London Stroke Register which had lower survival rates than ischemic strokes. Only 
few studies investigated time trends in long-term CFR, most of them showing decreasing 
CFR. For example, in a Danish population-based cohort found a decrease in 30-day and 5-
year mortality rates after IS between 1994-201123. In addition, in the Netherlands in a linkage 
study of national registries, age-and sex-specific 30-day and 1-year (excluding the first 30 
days) CFR decreased between 1997 and 2005 in most age-groups24. Controversially, 90-days 
CFR increased in the Swedish Stroke Registry between 1995 to 2010, which the authors 
referred to the higher proportion of more severe strokes25.  
 
To the best of our knowledge, our study is the first to investigate long-term time trends in 
CFR stratified by aetiological stroke subtypes according to standardized mechanism-based 
classification scheme such as the TOAST classification. The patterns of the stratified 5-year 
CFR by TOAST are in line with previously published data from our group reporting survival 
up to 2 years11. In the Nanjing Stroke Registry, highest one-year survival rates were reported 
for patients with SAO (92.7%), followed by UND (89.4%), CE (88.1%) and LAA (84.2%)26. 
Most CFRs in our study were lower compared to this data, and we found the lowest 1-year 
survival rates in CE (67.9%). Furthermore, the Dijon Stroke Registry analyzed 28-days CFR 
stratified by aetiology (defined as macroartheromics, microatheroma and cardioembolic). 
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They reported significantly improvements CFR in stroke due to microatheroma from 1985 to 
2004, similar to our findings27.  
 
The decrease in CFR might be caused by improvements in stroke management and treatment. 
For example, after the introduction of stroke units in 1994/1995 the number of stroke units, 
one of the most effective options in stroke management28, increased in Germany up to 255 in 
201229. Also, an increased uptake in acute therapies, such as thrombolytic therapy and 
improved overall care, might have led to the observed reduction in CFR in Germany. For 
example, based on German administrative hospital data proportion of stroke patients being 
admitted to a stroke unit increased between 2005 and 2010 from 15% to 52%30. The decrease 
in CFR might also be attributed to changes over time in patient characteristics affecting 
outcome such as stroke severity, comorbidities or frequency of early complications. For 
example, in the Austrian Stroke Unit Registry the stroke severity significantly decreased by 1 
Point in the National Institutes of Health Stroke Scale between 4 and 3 in men and between 5 
to 4 in women31.  
 
The recurrence rates observed in our study are in line with the pooled estimates of a recent 
meta-analysis based on population-based studies8. There are only a few studies reporting 
recurrence rates stratified by stroke aetiology. We found that patients with LAA have a high 
risk to get a second stroke within the first year, whereas after five years the risk in the LAA 
subgroup was relatively small in comparison to the other stroke subtypes. This higher risk 
might be because the CFR after 5 years in patients with LAA is high and, therefore, a 
substantial proportion of the patients died before they can get a second stroke. The rates in 
SAO are relatively low over the whole observation period. A previous systematic review 
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found lower recurrence rates up to 1 month in lacunar vs. non-lacunar infarctions, however, 
these differences were not statistically significant in time period up to 12 months32. The risk 
of a recurrent stroke in CE and UND remains high after the first year after the event. The high 
risk in CE might be attributable to patients with atrial fibrillation having a higher risk of 
recurrence33. The high risk of recurrent stroke in the UND group might be caused by a 
substantial proportion of patients with undetected AF in this group as recent studies revealed 
that intensified monitoring for AF in this group yield to a proportion of 16.1% patients with 
potential cardioembolic stroke34. 
 
We found no clear time trends in overall stroke recurrence rates as well after stratification for 
sex or stroke subtype in our main analysis using Cox regression, whereas we found a few 
significant time trends in stroke recurrence rates after taking competing risks into account. 
Our main analysis is in line with a systematic review from 2018 comprising 34 RCT, hospital-
based and community-based studies published before December 11, 2016, which also found 
no statistically significant time trends in stroke recurrence rates after ischemic stroke or 
transient ischemic attack35. The authors concluded that this might partly be due to 
heterogeneity in stroke aetiology as no stratification for stroke subtype was performed35. 
However, after stratification for ischemic stroke aetiology in our study, we did not find any 
clear time trend in recurrence rate in our main analysis despite substantial heterogeneity in 
stroke recurrence rates by aetiological subgroups. We only found a decrease in stroke 
recurrence rates over time in patients in the UND group, when we considered competing 
risks. One possible reason might be, that, although new medication for stroke prevention are 
available such as non-vitamin K oral anticoagulants, the control of cardiovascular risk factors 
(e.g. hypertension, atrial fibrillation) after a stroke is still not optimal in Germany36. Besides, 
adherence to secondary preventive measures might decrease during follow-up, leading to a 
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decrease in the effect of secondary prevention. An alternative explanation could be that our 
study was underpowered to detect a small decrease in stroke recurrence rates due to the small 
sample size, especially in the later years. Another reason might be that people die before they 
can get a second stroke. Therefore, we included as a sensitivity analysis an analysis 
accounting for competing risks, where we observed a significant decrease in stroke recurrence 
in total and in women.  
 
Our study has several strength and limitations. One of the strengths is the population-based 
design and the long-follow up over 20 years with constant standardized data collection over 
the entire time period. In addition, our data is able to report data on the TOAST classification 
of the first event over the whole time period which allows stratifying time trends in CFR and 
recurrence rates by aetiological subtypes of the first event. Our study also has several 
limitations. First, we have a high rate of undefined causes according to TOAST classification. 
However, the proportion of patient with undefined stroke is within the range of other 
population-based registers37, 38. Second, no information on the aetiological subtype of 
recurrent stroke was available, which might influence time trends in stroke recurrence. Third 
no adjustment for stroke severity was possible, as stroke severity is not collected in the 
register by a standardized scale such as the NIHSS. Fourth, the source population of our 
registry is relatively small, which might limit the statistical power of the study. However, the 
Erlanger Stroke Project is the largest and longest running population-based stroke registry in 







Decreasing CFR over the last 20 years were observed across all stroke subtypes that might be 
associated by improved acute treatment options. However, there is still room for improvement 
secondary prevention measures in ischemic stroke survivors, as we did not observe a clear 
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Figure 1. Survival probabilities (Kaplan-Meier estimates) after incident ischemic stroke 








Figure 2. Cumulative risk of recurrent stroke (1-Kaplan-Meier estimates) after incident 






Table 1. Survival probabilities for death after ischemic stroke stratified according to TOAST 
classification and sex 
TOAST 
categories 
 Survival probability in % (95%-CI) 
 Number at 
risk 
3 months 1 year 5 years 
     
All 3346 87.0 (85.9-88.2) 79.0 (77.7-80.5) 54.4 (52.5-56.4) 
     
Men 1563 90.7 (89.3-92.2) 82.8 (80.9-84.7) 59.2 (56.4-62.0) 
Women 1780 83.8 (82.1-85.5) 75.9 (73.9-77.9) 50.4 (47.9-53.1) 
     
LAA 272 82.4 (78.0-87.1) 73.7 (68.6-79.3) 49.4 (43.3-56.5) 
     
Men 159 84.4 (78.8-90.3) 75.5 (68.9-82.7) 53.8 (45.7-63.3) 
Women 113 79.6 (72.5-87.4) 71.3 (63.4-80.2) 43.7 (34.9-54.8) 
     
CE 742 80.0 (77.2–83.0) 67.9 (64.6-71.4) 40.9 (37.2–45.0) 
     
Men 321 86.1 (82.4–90.0) 74.0 (69.3–79.0) 47.8 (42.2-54.3) 
Women 421 75.5 (71.5-79.7) 63.4 (58.9-68.2) 35.7 (31.0-41.1) 
     
SAO 904 97.7 (96.8-98.7) 93.5 (91.9-95.2) 73.8 (70.4-77.3) 
     
Men 451 98.4 (97.3-99.6) 94.0 (91.8-96.3) 75.9 (71.3-80.9) 
Women 453 97.1 (95.5-98.7) 93.0 (90.6-95.4) 71.8 (67.1-76.9) 
     
UND 1245 86.2 (84.3-88.1) 77.7 (75.4-80.1) 50.3 (47.2-53.7) 
     
Men 554 90.8 (88.4-93.3) 81.8 (78.6-85.1) 54.3 (49.7-59.4) 
Women 691 82.5 (79.7-85.4) 74.5 (71.2-77.8) 47.2 (43.1-51.7) 
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Table 2. Hazard ratio for year of event for risk of death adjusted for age by Cox regression 
and stratified according to TOAST classification and sex. 
TOAST 
categories 







        
All 0.98 (0.97–0.99) <0.001 0.97 (0.96–0.99) <0.001 0.98 (0.97–0.99) <0.001 
LAA 1.00 (0.97–1.03) 0.816 1.00 (0.96–1.05) 0.914 0.99 (0.94–1.04) 0.579 
CE 0.98 (0.96–0.99) 0.010 0.97 (0.94–1.00) 0.020 0.98 (0.96–1.00) 0.106 
SAO 0.97 (0.95–1.00) 0.022 0.98 (0.95–1.02) 0.367 0.96 (0.93–0.99) 0.015 
UND 0.98 (0.97–1.00) 0.018 0.97 (0.94–0.99) 0.006 0.99 (0.97–1.01) 0.402 
       
  
*Adjusted for age and sex . p-values are for each HR of the continuous variable year of event.  
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Table 3. Cumulative risk of recurrent stroke (1 - Kaplan Meier estimator) stratified according 
to TOAST classification and sex 
 
TOAST categories  Stroke recurrence rates % (95%-CI) 
 Number at risk 3 months 1 year 5 years 
     
All 3346 3.1 (2.5-3.7) 7.5 (6.5-8.4) 20.1 (18.3-21.9) 
     
Men 1563 3.2 (2.3-4.1) 7.5 (6.1-8.9) 20.1 (17.5-22.7) 
Women 1780 3.0 (2.1-3.8) 7.5 (6.1-8.8) 20.1 (17.5-22.6) 
     
LAA 272 6.2 (3.1-9.2) 7.7 (4.2–11.0) 17.7 (11.4-23.6) 
     
Men 159 7.7 (3.2-12) 8.6 (3.8-13.1) 16.6 (8.7-23.9) 
Women 113 4.0 (0.1-7.8) 6.4 (1.3-11.2) 19.3 (8.6-28.8) 
     
CE 742 3.1 (1.8-4.5) 8.0 (5.7-10.2) 21.1 (16.9-25.1) 
     
Men 321 2.4 (0.6-4.2) 6.5 (3.5-9.5) 19.6 (13.7-25.1) 
Women 421 3.7 (1.7-5.6) 9.2 (5.9-12.4) 22.3 (16.2–28.0) 
     
SAO 904 1.8 (0.9-2.7) 5.6 (4.0-7.2) 17.2 (14.1-20.2) 
     
Men 451 2.1 (0.7-3.4) 6.1 (3.7-8.4) 18.4 (13.8-22.8) 
Women 453 1.6 (0.4-2.8) 5.2 (3.0-7.3) 16.0 (11.7-20.1) 
     
UND 1245 3.3 (2.3-4.3) 8.2 (6.5-9.9) 21.9 (18.7–25.0) 
     
Men 554 3.5 (1.9-5.1) 8.2 (5.7-10.7) 21.4 (16.7-25.9) 
Women 691 3.1 (1.7-4.5) 8.3 (5.9-10.6) 22.3 (17.8-26.6) 
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Table 4. Hazard Ratios for year of event for risk of stroke recurrence adjusted for age by Cox 
regression and stratified according to TOAST classification and sex 
TOAST 
categories 







       
All 0.99 (0.97–1.00) 0.160 1.00 (0.97–1.02) 0.837 0.98 (0.96–1.00) 0.073 
LAA 1.00 (0.93–1.06) 0.890 1.00 (0.92–1.08) 0.934 0.99 (0.88-1.10) 0.803 
CE 0.98 (0.94–1.02) 0.239 0.96 (0.91-1.02) 0.217 0.99 (0.94–1.04) 0.566 
SAO 1.00 (0.97-1.03) 0.856 1.02 (0.97-1.06) 0.608 0.98 (0.94–1.03) 0.406 
UND 0.99 (0.96–1.01) 0.339 1.00 (0.96-1.04) 0.972 0.98 (0.94–1.01) 0.191 
       
 
*Adjusted for age and sex, and interaction between age and sex 
# year of event was included as continuous factor 
+Adjusted for age and sex 
 
